Stock Ratings / Health Care / BIVI / earnings

CALC (47) ASBP (33) BOLT (28) HIND (35) ⌘ Pro Terminal →

BioVie Inc. (Class A) (BIVI) Next Earnings Date & Expected ±12.5% Move

$1.38 -5.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

BioVie Inc. (Class A) (BIVI) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $12.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BIVI)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 28, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.17 Expected Swing

MODEL EARNINGS SETUP GAUGE

BIVI Quantitative Pre-Earnings Setup: 33/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (33/100)Model Risk Weight (67/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-06-30	$0	-$17.5M	-$19.0M	52%
FY 2024	2024-06-30	$0	-$32.1M	-$27.9M	52%
FY 2023	2023-06-30	$0	-$50.3M	-$40.3M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BIVI)

✓Walkthrough of BIVI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BIVI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.36%⚡ TESTING RESISTANCE

2026-10-30O $1.39H $1.49L $1.38C $1.38VOL 105.1K

RES: $1.44SUP: $1.18SMA50: $1.64SMA200: $1.52

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BIVI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BIVI Butterfly Map → + Track BIVI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BIVI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BIVI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BIVI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BIVI)

Health Care Rank #881 of 1016 ⚔️ CALC vs BIVI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BIVI vs. CALC, ASBP, BOLT, HIND)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioVie Inc. (Class A) (BIVI) ranks #881 by composite RQD confidence (33/100, grade E) and #879 by equity capitalization ($12.0M). Within this direct 5-issuer industry benchmark cohort, BIVI leads on earnings valuation at N/A trailing P/E, while BIVI leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CALC currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with BIVI at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BIVI ACTIVE BioVie Inc. (Class A)	E	33/100	—	—	-35.0%	-5.48%	$12.0M	Benchmark Subject
CALC CalciMedica Inc.	D	47/100	—	—	-35.0%	+5.42%	$11.9M	/calc-vs-bivi →
ASBP Aspire-Lakewood Holdings Inc.	E	33/100	—	-1.9%	-35.0%	-4.50%	$11.9M	/asbp-vs-bivi →
BOLT Bolt Biotherapeutics Inc.	E	28/100	—	—	-35.0%	-3.34%	$12.3M	/bolt-vs-bivi →
HIND Vyome Holdings Inc.	D-	35/100	—	68.4%	-35.0%	+1.74%	$12.3M	/hind-vs-bivi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001580149

In its most recent audited fiscal period (FY2025, filed 2025-06-30), BioVie Inc. (Class A) (BIVI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$17.5M, operating cash flow of -$19.0M, and free cash flow of -$19.0M (+31.9% YoY). On the balance sheet, BIVI closed FY2025 with $22.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$0	-$17.5M	-$19.0M	-$19.0M	$22.5M	—
FY2024 (FY)	2024-06-30	$0	-$32.1M	-$27.9M	-$27.9M	$25.7M	—
FY2023 (FY)	2023-06-30	$0	-$50.3M	-$40.3M	-$40.3M	—	—

3. BIVI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BIVI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, BioVie Inc. (Class A) (NASDAQ: BIVI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.38 (-5.48% 1D, market cap $12.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BIVI ranks #881 in composite RQD confidence.

How does BIVI compare to CALC and ASBP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BIVI carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CALC (CalciMedica Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and ASBP (Aspire-Lakewood Holdings Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M). Among the 5-stock peer group, BIVI leads on earnings multiple (N/A) while BIVI leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BIVI?

Per BIVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001580149), BioVie Inc. (Class A) generated $0 in revenue, -$17.5M in net income, and -$19.0M in free cash flow against $22.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BIVI trading relative to its 50-day, 200-day, and 52-week technical levels?

BIVI last traded at $1.38 (-5.48% on volume of 41,879 shares), positioning the stock -15.85% below its 50-day simple moving average ($1.64) and -9.21% below its 200-day simple moving average ($1.52). Across its 52-week range of $0.82 to $3.79, BIVI sits at the 18.9% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.21 to $1.55).